Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.43 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 2/20 | 0.42 |
| ▸ | CES1 | P23141 | 2/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 2/20 | 0.42 |
| ▸ | TYK2 | P29597 | 2/20 | 0.42 |
| ▸ | KRAS | P01116 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 3/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.40 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28262394 | 0.98 | LMNA (0.43) | LMNAHTTKMT2APARP10PARP15 | |
| SCHEMBL3395132 | 0.86 | PARP1 (0.47) | KMT2APARP10NPC1SMN1; SMN2RAB9A | |
| SCHEMBL28266600 | 0.85 | CES2 (0.45) | KMT2ANPC1SMN1; SMN2CES2CES1 | |
| SCHEMBL1261333 | 0.83 | KMT2A (0.50) | LMNAKMT2ANPC1SMN1; SMN2CES2 | |
| SCHEMBL29933044 | 0.83 | ALB (0.55) | HTTKMT2ANPC1SMN1; SMN2CES2 | |
| SCHEMBL184046 | 0.83 | ALB (0.55) | HTTKMT2ANPC1SMN1; SMN2CES2 | |
| SCHEMBL27675594 | 0.82 | KMT2A (0.48) | KMT2ANPC1SMN1; SMN2RAB9AKDM4E | |
| SCHEMBL24916 | 0.81 | ALDH1A1 (0.57) | KMT2ANPC1SMN1; SMN2CES2CES1 | |
| SCHEMBL4135906 | 0.81 | F10 (0.41) | KMT2ANPC1SMN1; SMN2CES2CES1 | |
| SCHEMBL5444249 | 0.81 | TSHR (0.48) | LMNAKMT2ANPC1SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012014127-A1 | 5-LIPOXYGENASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2012-02-02 | — | — | WO | claimed |
| EP-1928465-A1 | BENZODIAZEPINE DERIVATIVES FOR TREATING HEPATITIS C INFECTION | Arrow Therapeutics Limited (GB) | 2008-06-11 | — | — | EP | claimed |
| CN-1309715-C | N-acylaminoacetonitrile derivatives and their use for controlling parasites | NOVARTIS AG (CH) | 2007-04-11 | — | — | CN | claimed |
| WO-2007034127-A1 | BENZODIAZEPINE DERIVATIVES FOR TREATING HEPATITIS C INFECTION | ARROW THERAPEUTICS LIMITED (GB) | 2007-03-29 | — | — | WO | claimed |
| WO-2025078808-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2025-04-17 | — | — | WO | disclosed |
| CN-118044519-A | Molecules having pesticidal utility, and intermediates, compositions and methods related thereto | 科迪华农业科技有限责任公司 | 2024-05-17 | — | — | CN | disclosed |
| CN-110072842-B | Molecules having pesticidal utility, and intermediates, compositions and methods related thereto | 科迪华农业科技有限责任公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-114634512-B | Compounds as inhibitors of bruton's tyrosine kinase, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2023-11-14 | — | — | CN | disclosed |
| WO-2023165570-A1 | CYCLOALKYL OR HETEROCYCLYL SUBSTITUTED HETEROARYL COMPOUND, AND COMPOSITION AND USE THEREOF | 深圳市塔吉瑞生物医药有限公司 | 2023-09-07 | — | — | WO | disclosed |
| US-20230192691-A1 | HETEROCYCLIC COMPOUNDS AS BTK INHIBITORS | BEIJING INNOCARE PHARMA TECH CO LTD (CN) | 2023-06-22 | — | — | US | disclosed |
| US-11618753-B2 | Aminopyrrolotriazines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-04-04 | — | — | US | disclosed |
| CN-114716381-A | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-101360498-A | Calcilytic compounds | SMITHKLINE BEECHAM CORP (US) | 2009-02-04 | — | — | CN | disclosed |
| EP-1951244-A2 | CALCILYTIC COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007062370-A2 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007062370-A2 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-31 | — | — | WO | disclosed |
| CN-1309715-C | N-acylaminoacetonitrile derivatives and their use for controlling parasites | NOVARTIS AG (CH) | 2007-04-11 | — | — | CN | disclosed |
| CN-1602296-A | Amidoacetonitrile derivatives | NOVARTIS AG (CH) | 2005-03-30 | — | — | CN | disclosed |
| CN-1046939-C | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors | BYK GULDEN LOMBERG CHEM FAB (DE) | 1999-12-01 | — | — | CN | disclosed |
| CN-1126468-A | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors | BYK GULDEN LOMBERG CHEM FAB (DE) | 1996-07-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192691-A1 | HETEROCYCLIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LYN | LMNA 3949/4885HTT 1747/4885KMT2A 1636/4885 |
| US-11618753-B2 | Aminopyrrolotriazines as kinase inhibitors | RIPK1, RIPK2, RIPK4 | LMNA 3691/4885HTT 4188/4885KMT2A 3048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.